Keeping Pharma’s House in Order
Bribery and corruption are two major problems in any industry, and Big Pharma
is not exempt. As regulators look to tackle this problem, coming down hard
on perpetuators, pharma companies need to ensure that their compliance
programmes are in place and updated to reflect new developments in the law.
Originally published in the December 2012 issue of Innovations in Pharmaceutical Technology (IPT).
Read the article here